Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of ICP-B208 in Patients With Advanced Solid Tumors
Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Summary
To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B208 in the trial participants of unresectable advanced or metastatic solid tumors
Official title: An Open, Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Efficacy of ICP-B208 in Participants of Advanced Solid Tumor Trials
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
539
Start Date
2026-07-03
Completion Date
2031-06
Last Updated
2026-07-10
Healthy Volunteers
No
Conditions
Interventions
ICP-B208
ICP-B208 will be administered by intravenous infusion every 3 weeks (Q3W) until disease progression (PD) or the occurrence of unacceptable toxicity or withdrawal from the study for other reasons (whichever occurs first).
Locations (1)
Beijing Cancer Hospital
Beijing, Beijing Municipality, China